ID   BL-30
AC   CVCL_C142
SY   BL30; BL 30; BL 030; IARC/BL30; IARC/BL 30; IARC-BL30; IARC BL30; IARC BL 30
DR   cancercelllines; CVCL_C142
DR   Cosmic; 2814532
DR   DSMZ; ACC-916
DR   DSMZCellDive; ACC-916
DR   IARC_TP53; 701
DR   Wikidata; Q54797136
RX   PubMed=1356511;
RX   PubMed=1915267;
RX   PubMed=2825176;
RX   PubMed=3934070;
RX   PubMed=6090749;
RX   PubMed=6231253;
RX   PubMed=8515068;
RX   PubMed=8896424;
RX   PubMed=9973220;
RX   PubMed=11793449;
RX   PubMed=22885699;
RX   PubMed=24590883;
RX   PubMed=25960936;
CC   From: International Agency of Research on Cancer (IARC); Lyon; France.
CC   Population: Caucasian.
CC   Virology: EBV-negative.
CC   Doubling time: 15-24 hours (Note=Depending on cell density) (DSMZ=ACC-916).
CC   HLA typing: A*01:01,11:01; B*08:01,39:01; C*02:02,07:01; DQA1*01:03,05:01; DQB1*02:01,06:03; DRB1*03:01,13:01 (PubMed=25960936).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Thr (c.737T>C); ClinVar=VCV000428886; Zygosity=Unspecified (PubMed=1915267).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
CC   Cell type: B-cell; CL=CL_0000236.
ST   Source(s): DSMZ=ACC-916
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 11,12
ST   D16S539: 11,12
ST   D18S51: 12,13
ST   D19S433: 13,14
ST   D21S11: 30,31.2
ST   D2S1338: 19,24
ST   D3S1358: 17,18
ST   D5S818: 11
ST   D7S820: 8,12
ST   D8S1179: 10,13
ST   FGA: 23,25
ST   Penta D: 8,9
ST   Penta E: 12,16
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 14,15
DI   NCIt; C2912; Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_M567 ! BL-28
OI   CVCL_C144 ! BL-32
OI   CVCL_IV21 ! IARC-139
SX   Male
AG   19Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 02-05-24; Version: 21
//
RX   PubMed=1356511; DOI=10.1182/blood.V80.7.1781.1781;
RA   Gaidano G., Hauptschein R.S., Parsa N.Z., Offit K., Rao P.H.,
RA   Lenoir G.M., Knowles D.M., Chaganti R.S.K., Dalla-Favera R.;
RT   "Deletions involving two distinct regions of 6q in B-cell non-Hodgkin
RT   lymphoma.";
RL   Blood 80:1781-1787(1992).
//
RX   PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x;
RA   Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T.;
RT   "p53 is frequently mutated in Burkitt's lymphoma cell lines.";
RL   EMBO J. 10:2879-2887(1991).
//
RX   PubMed=2825176; DOI=10.1073/pnas.84.22.8060;
RA   Calender A., Billaud M., Aubry J.-P., Banchereau J., Vuillaume M.,
RA   Lenoir G.M.;
RT   "Epstein-Barr virus (EBV) induces expression of B-cell activation
RT   markers on in vitro infection of EBV-negative B-lymphoma cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:8060-8064(1987).
//
RX   PubMed=3934070;
RA   Lenoir G.M., Vuillaume M., Bonnardel C.;
RT   "The use of lymphomatous and lymphoblastoid cell lines in the study of
RT   Burkitt's lymphoma.";
RL   IARC Sci. Publ. 60:309-318(1985).
//
RX   PubMed=6090749; DOI=10.1093/jnci/73.4.835;
RA   Philip I., Philip T., Favrot M.-C., Vuillaume M., Fontaniere B.,
RA   Chamard D., Lenoir G.M.;
RT   "Establishment of lymphomatous cell lines from bone marrow samples
RT   from patients with Burkitt's lymphoma.";
RL   J. Natl. Cancer Inst. 73:835-840(1984).
//
RX   PubMed=6231253; DOI=10.1002/ijc.2910330407;
RA   Ehlin-Henriksson B., Klein G.;
RT   "Distinction between Burkitt lymphoma subgroups by monoclonal
RT   antibodies: relationships between antigen expression and type of
RT   chromosomal translocation.";
RL   Int. J. Cancer 33:459-463(1984).
//
RX   PubMed=8515068; DOI=10.4049/jimmunol.150.12.5418;
RA   Jain V.K., Judde J.-G., Max E.E., Magrath I.T.;
RT   "Variable IgH chain enhancer activity in Burkitt's lymphomas suggests
RT   an additional, direct mechanism of c-myc deregulation.";
RL   J. Immunol. 150:5418-5428(1993).
//
RX   PubMed=8896424; DOI=10.1182/blood.V88.9.3562.bloodjournal8893562;
RA   Chapman C.J., Zhou J.X., Gregory C.D., Rickinson A.B., Stevenson F.K.;
RT   "VH and VL gene analysis in sporadic Burkitt's lymphoma shows somatic
RT   hypermutation, intraclonal heterogeneity, and a role for antigen
RT   selection.";
RL   Blood 88:3562-3568(1996).
//
RX   PubMed=9973220;
RA   Gutierrez M.I., Cherney B.W., Hussain A., Mostowski H.S., Tosato G.,
RA   Magrath I.T., Bhatia K.G.;
RT   "Bax is frequently compromised in Burkitt's lymphomas with
RT   irreversible resistance to Fas-induced apoptosis.";
RL   Cancer Res. 59:696-703(1999).
//
RX   PubMed=11793449; DOI=10.1002/gcc.10022;
RA   Sobol H., Benziane A., Kerangueven F., Yin L., Noguchi T., Pauly S.,
RA   Eisinger F., Longy M., Romeo G., Lenoir G.M., Birnbaum D.;
RT   "Genome-wide search for loss of heterozygosity in Burkitt lymphoma
RT   cell lines.";
RL   Genes Chromosomes Cancer 33:217-224(2002).
//
RX   PubMed=22885699; DOI=10.1038/nature11378;
RA   Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W.-M., Zhang M.-L.,
RA   Wright G., Shaffer A.L. III, Hodson D.J., Buras E., Liu X.-L., Powell J.I.,
RA   Yang Y.-D., Xu W.-H., Zhao H., Kohlhammer H., Rosenwald A., Kluin P.M.,
RA   Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M.,
RA   Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B.,
RA   Ogwang M.D., Reynolds S.J., Fisher R.I., Braziel R.M., Tubbs R.R.,
RA   Cook J.R., Weisenburger D.D., Chan W.C., Pittaluga S., Wilson W.,
RA   Waldmann T.A., Rowe M., Mbulaiteye S.M., Rickinson A.B., Staudt L.M.;
RT   "Burkitt lymphoma pathogenesis and therapeutic targets from structural
RT   and functional genomics.";
RL   Nature 490:116-120(2012).
//
RX   PubMed=24590883; DOI=10.1002/gcc.22161;
RA   Murga Penas E.-M., Schilling G., Behrmann P., Klokow M.,
RA   Vettorazzi E., Bokemeyer C., Dierlamm J.;
RT   "Comprehensive cytogenetic and molecular cytogenetic analysis of 44
RT   Burkitt lymphoma cell lines: secondary chromosomal changes
RT   characterization, karyotypic evolution, and comparison with primary
RT   samples.";
RL   Genes Chromosomes Cancer 53:497-515(2014).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//